Osmotica Pharmaceuticals revenue increased from $237.7 million in 2017 to $263.7 million in 2018, a 11% increase.

Annual Revenue ($)

Osmotica Pharmaceuticals revenue was $263.70 m in FY, 2018

Quarterly Revenue ($)

FY, 2016FY, 2017FY, 2018
Revenue$170.52 m$237.67 m$263.70 m
Q3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019
Revenue$53.74 m$66.34 m$57.13 m$57.53 m$65.46 m

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Osmotica Pharmaceuticals revenue breakdown by business segment: 17.0% from Lorzone, 9.3% from Divigel, 15.0% from Venlafaxine ER, 7.5% from OB Complete and 51.2% from Other

FY, 2017FY, 2016
Lorzone22.28 m29 m
Divigel18.54 m15.85 m
Venlafaxine ER96.05 m25.57 m
OB Complete10.45 m12.76 m
Other46.64 m87.34 m
Methylphenidate43.71 m

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.